相关实验视频
Updated: Jan 11, 2026
05:17
Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
Published on: April 18, 2025
781
药物配方和分析方法的多尼佩西尔
Vu Dang Hoang1, Hue Minh Thi Nguyen2, Tuan Anh Nguyen3,4,5
1Faculty of Analytical Chemistry and Drug Quality Control, Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi, Vietnam. hoangvd@hup.edu.vn.
AAPS PharmSciTech
|November 11, 2025
概括
本综述探讨了阿尔茨海默病治疗方法多内佩西尔的先进药物配方和分析方法. 药物输送和质量控制方面的创新对于改善患者的治疗结果和确保治疗有效性至关重要.
科学领域:
- 制药科学 制药科学
- 分析化学 分析化学
- 神经科学是一个神经科学.
背景情况:
- 多尼佩西尔是阿尔茨海默病 (AD) 的关键乙胆酶抑制剂.
- 随着治疗需求的不断变化,药物质量,疗效,安全性和患者服药性方面的进步变得必不可少.
- 药物配方和分析方法对于优化AD治疗至关重要.
研究的目的:
- 审查最近在多尼佩西尔制药配方中的创新.
- 总结了多尼素表征和质量控制分析方法的进展.
- 要突出配方与分析科学之间的协同作用,以增强多尼佩西尔治疗.
主要方法:
- 文献综述侧重于donepezil的药物配方和分析技术.
- 探索新型药物输送系统 (脂质体,纳米颗粒,微针,鼻凝,存储器).
- 分析方法的审查,包括RP-HPLC,LC-MS/MS,奇拉分离,电化学和光谱学.
主要成果:
- 新型配方旨在改善大脑准,延长释放,并最大限度地减少副作用.
- 先进的分析方法可以在各种矩阵中进行精确的量化和表征.
- 经过验证的方法对于配方性能评估,稳定性监测和法规遵守至关重要.
结论:
- 制药配方的进步是开发增强的多尼佩西尔输送系统的关键.
- 分析科学的进步对于确保donepezil产品的质量和有效性至关重要.
- 制定和分析策略的综合开发对于优化基于donepezil的阿尔茨海默病管理至关重要.
相关概念视频
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
293
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
293
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
192
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
192
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
141
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
141
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
168
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
168
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
01:22Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782